MX2015011202A - Derivados de 2-acilaminotiazol o su sal. - Google Patents
Derivados de 2-acilaminotiazol o su sal.Info
- Publication number
- MX2015011202A MX2015011202A MX2015011202A MX2015011202A MX2015011202A MX 2015011202 A MX2015011202 A MX 2015011202A MX 2015011202 A MX2015011202 A MX 2015011202A MX 2015011202 A MX2015011202 A MX 2015011202A MX 2015011202 A MX2015011202 A MX 2015011202A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- bladder
- muscarinic
- receptor
- alkyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 abstract 3
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 208000026723 Urinary tract disease Diseases 0.000 abstract 2
- 208000029162 bladder disease Diseases 0.000 abstract 2
- 230000008602 contraction Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000014001 urinary system disease Diseases 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000004168 Underactive Urinary Bladder Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- -1 cyclic amine Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229940126027 positive allosteric modulator Drugs 0.000 abstract 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical group NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 150000007979 thiazole derivatives Chemical class 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Problema Se proporciona un compuesto que es de utilidad como un ingrediente activo de una composición farmacéutica para el tratamiento de disfunciones de almacenamiento, disfunciones de evacuación y enfermedades del tracto urinario inferior. [Medios de solución] Los presentes inventores hallaron que un derivado de tiazol con pirazin-2-carbonilamino sustituido en la posición 2 es un excelente modulador alostérico positivo del receptor muscarínico M3 y es de utilidad como un agente para prevenir y/o tratar enfermedades de la vejiga o del tracto urinario, relacionadas con la contracción de la vejiga por el receptor muscarínico M3, completando así la presente invención. El derivado de 2-acilaminotiazol o una de sus sales de la presente invención se puede usar como un agente para prevenir y/o tratar enfermedades de la vejiga o del tracto urinario, relacionadas con la contracción de la vejiga por el receptor muscarínico M3, por ejemplo, disfunciones de evacuación como vejiga hipoactiva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013039964 | 2013-02-28 | ||
| PCT/JP2014/054803 WO2014133056A1 (ja) | 2013-02-28 | 2014-02-27 | ２－アシルアミノチアゾール誘導体またはその塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015011202A true MX2015011202A (es) | 2016-05-18 |
| MX368539B MX368539B (es) | 2019-10-07 |
Family
ID=51428316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011202A MX368539B (es) | 2013-02-28 | 2014-02-27 | Derivados de 2-acilaminotiazol o su sal. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9562044B2 (es) |
| EP (1) | EP2963036B1 (es) |
| JP (1) | JP6183451B2 (es) |
| KR (1) | KR102164821B1 (es) |
| CN (1) | CN105008353B (es) |
| AR (1) | AR094921A1 (es) |
| AU (1) | AU2014221726B2 (es) |
| BR (1) | BR112015020963B1 (es) |
| CA (1) | CA2902302C (es) |
| EA (1) | EA027179B1 (es) |
| ES (1) | ES2748402T3 (es) |
| IL (1) | IL240764A0 (es) |
| MX (1) | MX368539B (es) |
| MY (1) | MY190361A (es) |
| PH (1) | PH12015501899A1 (es) |
| PL (1) | PL2963036T3 (es) |
| PT (1) | PT2963036T (es) |
| SA (1) | SA515360956B1 (es) |
| SG (1) | SG11201506713TA (es) |
| TW (1) | TWI647227B (es) |
| UA (1) | UA118445C2 (es) |
| WO (1) | WO2014133056A1 (es) |
| ZA (1) | ZA201506296B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3150581T3 (pl) * | 2014-05-28 | 2020-07-13 | Astellas Pharma Inc. | Pochodne pirydyny |
| MX370140B (es) * | 2014-06-06 | 2019-12-03 | Astellas Pharma Inc | Derivado de 2-acilaminotiazol o sal del mismo. |
| JP6569678B2 (ja) | 2014-08-26 | 2019-09-04 | アステラス製薬株式会社 | ２−アミノチアゾール誘導体またはその塩 |
| US10005762B2 (en) | 2014-12-05 | 2018-06-26 | Astellas Pharma Inc. | Pyridine derivatives |
| AR102849A1 (es) * | 2015-03-09 | 2017-03-29 | Astellas Pharma Inc | Compuesto de piridina bicíclica |
| EP3290037A4 (en) * | 2015-04-28 | 2019-01-23 | Astellas Pharma Inc. | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION |
| EP3297528B1 (en) * | 2015-05-20 | 2020-08-05 | Kent Imaging | Automatic compensation for the light attenuation due to epidermal melanin in skin images |
| MY202833A (en) | 2018-05-08 | 2024-05-24 | Nippon Shinyaku Co Ltd | Azabenzimidazole compounds and pharmaceutical |
| RU2709496C1 (ru) * | 2019-08-01 | 2019-12-18 | Марат Феликсович Фазылов | Способ получения аватромбопага |
| CA3161582A1 (en) | 2019-11-13 | 2021-05-20 | Nippon Shinyaku Co., Ltd. | Azabenzimidazole compound and medicine |
| CA3179059A1 (en) * | 2020-06-09 | 2021-12-16 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
| EP3967311A1 (en) | 2020-09-11 | 2022-03-16 | Astellas Pharma Inc. | Compounds for use in the treatment of dry mouth |
| WO2026127686A1 (ko) * | 2024-12-11 | 2026-06-18 | 주식회사 프리모테라 | 당단백질130 억제제로서 신규한 화합물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1466912E (pt) | 2002-01-18 | 2013-06-28 | Astellas Pharma Inc | Derivado de 2-aciloaminotiazol ou seu sal |
| AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| CN100445281C (zh) * | 2003-05-02 | 2008-12-24 | 诺瓦提斯公司 | 与毒蕈碱性m3受体结合的奎宁环衍生物 |
| JP4324791B2 (ja) | 2003-07-17 | 2009-09-02 | アステラス製薬株式会社 | ２−アシルアミノチアゾール誘導体又はその塩 |
| JP4665769B2 (ja) * | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
| JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| HUE052110T2 (hu) | 2010-07-29 | 2021-04-28 | Rigel Pharmaceuticals Inc | AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk |
-
2014
- 2014-02-26 TW TW103106494A patent/TWI647227B/zh not_active IP Right Cessation
- 2014-02-27 MX MX2015011202A patent/MX368539B/es active IP Right Grant
- 2014-02-27 PT PT147573778T patent/PT2963036T/pt unknown
- 2014-02-27 ES ES14757377T patent/ES2748402T3/es active Active
- 2014-02-27 US US14/770,648 patent/US9562044B2/en not_active Expired - Fee Related
- 2014-02-27 MY MYPI2015702844A patent/MY190361A/en unknown
- 2014-02-27 JP JP2015503003A patent/JP6183451B2/ja not_active Expired - Fee Related
- 2014-02-27 KR KR1020157026269A patent/KR102164821B1/ko not_active Expired - Fee Related
- 2014-02-27 EP EP14757377.8A patent/EP2963036B1/en active Active
- 2014-02-27 AU AU2014221726A patent/AU2014221726B2/en not_active Ceased
- 2014-02-27 AR ARP140100632A patent/AR094921A1/es unknown
- 2014-02-27 SG SG11201506713TA patent/SG11201506713TA/en unknown
- 2014-02-27 EA EA201591391A patent/EA027179B1/ru not_active IP Right Cessation
- 2014-02-27 WO PCT/JP2014/054803 patent/WO2014133056A1/ja not_active Ceased
- 2014-02-27 UA UAA201508421A patent/UA118445C2/uk unknown
- 2014-02-27 BR BR112015020963-7A patent/BR112015020963B1/pt not_active IP Right Cessation
- 2014-02-27 CN CN201480010396.6A patent/CN105008353B/zh not_active Expired - Fee Related
- 2014-02-27 PL PL14757377T patent/PL2963036T3/pl unknown
- 2014-02-27 CA CA2902302A patent/CA2902302C/en not_active Expired - Fee Related
-
2015
- 2015-08-23 IL IL240764A patent/IL240764A0/en active IP Right Grant
- 2015-08-27 SA SA515360956A patent/SA515360956B1/ar unknown
- 2015-08-27 ZA ZA2015/06296A patent/ZA201506296B/en unknown
- 2015-08-27 PH PH12015501899A patent/PH12015501899A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA118445C2 (uk) | Похідне 2-ациламінотіазолу або його сіль | |
| PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
| JO3114B1 (ar) | مركبات بيريدازينون | |
| PH12016501582A1 (en) | Fused heterocyclic compound | |
| PH12016501614A1 (en) | Heterocyclic compound | |
| MA40170A (fr) | Dérivés hétérocycliques de morphinan et leur utilisation | |
| MY178760A (en) | Monocyclic pyridine derivative | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| MX2016010572A (es) | Compuestos heterociclicos aromaticos como compuestos antiinflamatorios. | |
| JO3317B1 (ar) | مركبات تترا هيدروبيرولو ثيازين | |
| MA40171A (fr) | Dérivés d'azamophinan et leur utilisation | |
| PH12015501037A1 (en) | Pyridine derivative | |
| MX2016017147A (es) | Compuestos de indazole substituidos como inhibidores de irak4. | |
| MX369801B (es) | Compuesto heterociclico sustituido con halogeno. | |
| MX2016007861A (es) | Compuestos de ácido dimetilbenzoico. | |
| AR080969A1 (es) | Compuesto biciclico | |
| TW201613914A (en) | 2-acylaminothiazole derivative or salt thereof | |
| EP3769757A3 (en) | Imaging histone deacetylases with a radiotracer using positron emission tomography | |
| MX2015006930A (es) | Compuestos de isoxazol amina sustituidos como inhibidores de scd1. | |
| PH12015502032A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX2016004967A (es) | Tratamiento para cancer pancreatico. | |
| CY1119483T1 (el) | Θεραπευτικος παραγων για τις αγχωδεις διαταραχες | |
| MX2015002705A (es) | Compuestos de piridinona para usarse en terapia fotodinamica. | |
| PH12016501645A1 (en) | Aminopyrazolone derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |